Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer

NCT04941885 · clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
78
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Sun Yat-sen University